8 completed, 1 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow tigatuzumab: new trials by email Literature Review of tigatuzumab trials Research Report on tigatuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer Abraxane alone, Abraxane + Tigatuzumab - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Completed | University of Alabama at Birmingham | 64 | 2011-03-01 | 2017-10-26 |
| A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer CS-1008 - Colorectal Neoplasms | Phase 1 | Completed | Ludwig Institute for Cancer Research | 19 | 2010-10-12 | 2022-10-28 |
| CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer CS-1008 2 mg/kg, Sorafenib, CS-1008 6/2 mg/kg - Advanced Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Completed | Daiichi Sankyo | 172 | 2010-07-09 | 2021-04-08 |
| Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments CS-1008, FOLFIRI - Metastatic Colorectal Cancer | Phase 1 | Completed | Daiichi Sankyo | 21 | 2010-05-01 | 2013-12-03 |
| Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer CS-1008, Paclitaxel, Carboplatin - Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV | Phase 2 | Completed | Daiichi Sankyo | 24 | 2009-10-06 | 2021-04-08 |
| CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin CS-1008, irinotecan - Metastatic Colorectal Cancer | Phase 2 | Terminated | Daiichi Sankyo | 8 | 2009-07-01 | 2012-01-31 |
| CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) CS-1008, Placebo, Paclitaxel - Non-small Cell Lung Cancer | Phase 2 | Completed | Daiichi Sankyo | 109 | 2009-06-01 | 2012-09-10 |
| Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer CS-1008 (humanized anti-DR5 antibody), gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Daiichi Sankyo | 65 | 2007-08-15 | 2021-04-08 |
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) CS-1008 (humanized anti-DR5 antibody) - Malignancies, Lymphoma | Phase 1 | Completed | Daiichi Sankyo | 40 | 2007-09-11 |
Colorectal Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Liver Neoplasms (1) · Lymphoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Daiichi Sankyo (7) · Ludwig Institute for Cancer Research (1) · University of Alabama at Birmingham (1)
United States (6) · Australia (1) · Germany (1) · Japan (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Andres Forero, M.D. (1) · Andrew M Scott, MBBS, MD, FRACP, DDU (1)